Tumor infiltrating lymphocytes as an endpoint in cancer vaccine trials
Checkpoint inhibitors have invigorated cancer immunotherapy research, including cancer vaccination. Classic early phase trial design and endpoints used in developing chemotherapy are not suited for evaluating all forms of cancer treatment. Peripheral T cell response dynamics have demonstrated incons...
Main Authors: | Patrick M. McCarthy, Franklin A. Valdera, Todd R. Smolinsky, Alexandra M. Adams, Anne E. O’Shea, Katryna K. Thomas, Spencer Van Decar, Elizabeth L. Carpenter, Ankur Tiwari, John W. Myers, Diane F. Hale, Timothy J. Vreeland, George E. Peoples, Alex Stojadinovic, Guy T. Clifton |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1090533/full |
Similar Items
-
Utility of cell-based vaccines as cancer therapy: Systematic review and meta-analysis
by: Ankur Tiwari, et al.
Published: (2024-12-01) -
Correlates of protection for inactivated enterovirus 71 vaccine: the analysis of immunological surrogate endpoints
by: Wenbo Zhu, et al.
Published: (2017-09-01) -
A comparison of the test-negative and the matched case-control study designs for estimation of EV71 vaccine immunological surrogate endpoints from a randomized controlled trial
by: Li Zhang, et al.
Published: (2022-11-01) -
Study of methods for endpoint aware inspection in a next generation firewall
by: Jenny Heino, et al.
Published: (2022-09-01) -
Surrogate endpoints in trials: a call for better reporting
by: Oriana Ciani, et al.
Published: (2022-12-01)